Humana Reaffirms Full-Year 2026 EPS Guidance Ahead of Investor Meetings

Executive Summary

On September 1, 2026, Humana Inc. filed a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) to disclose that senior management is participating in investor and analyst meetings throughout September 2026 and reaffirming its FY 2026 financial outlook.

---

Guidance Reaffirmation Details

Humana reaffirmed its full-year 2026 financial outlook, which remains unchanged from the guidance provided in its July 29, 2026 earnings release:

• GAAP Diluted EPS: Projected at at least $6.52
• Adjusted (Non-GAAP) EPS: Projected at at least $9.00

GAAP to Non-GAAP FY 2026 EPS Reconciliation:

Item	Per Share Amount
GAAP Diluted EPS	at least $6.52
Amortization of identifiable intangibles	$0.30
Put/call valuation adjustments (minority interest)	$1.47
Value creation initiatives	$1.27
Impairment charges	$0.17
Cumulative net tax impact	$(0.73)
Adjusted (Non-GAAP) Diluted EPS	at least $9.00

---

Key Regulatory / Policy Note

• CMS Star Ratings: Humana explicitly noted that it will withhold commentary regarding 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028) until the Centers for Medicare and Medicaid Services (CMS) publishes official final ratings data in October 2026.

---

Market & Trading Implications

• Trading Significance: Low
• The filing represents a scheduled reaffirmation of existing full-year 2026 targets ahead of broker conferences and investor meetings during September 2026. No unexpected revisions to financial targets were introduced.